Corlanor (ivabradine) is expensive primarily because it is a brand-name drug with no generic competition in the United States, made by Amgen for a relatively small patient population. The retail price typically runs between $400 and $500 for a 30-day supply, though out-of-pocket costs vary widely depending on insurance. Several factors stack on top of each other to keep the price high.
A Small, Specialized Patient Population
Corlanor is FDA-approved for a narrow group: people with chronic heart failure whose hearts still pump too fast despite being on maximum doses of beta-blockers, or who can’t tolerate beta-blockers at all. Beta-blockers are the first-line treatment and cost pennies per pill as generics. Corlanor only enters the picture when those cheaper drugs fall short.
The reasons patients can’t use or fully tolerate beta-blockers include low blood pressure, reactive airway disease like asthma, and excessive heart rate slowing. For those patients, ivabradine fills a gap because it works through a completely different mechanism. It targets a specific type of ion channel in the heart’s natural pacemaker cells, slowing the heart rate without lowering blood pressure, reducing the heart’s pumping strength, or affecting the lungs. That precision is clinically valuable, but it also means the drug serves a fraction of all heart failure patients rather than a mass market. Smaller patient populations mean fewer prescriptions over which a manufacturer can spread its research, manufacturing, and marketing costs.
No Generic Competition Yet
Generic drugs typically bring prices down 80% or more, but Corlanor has faced a long road to generic entry. FDA records show patent certification activity tied to Corlanor’s 5 mg and 7.5 mg tablets, with key dates extending into 2026. Until generic manufacturers can legally enter the market, Amgen has no price competition from equivalent products. This single factor is the largest driver of the drug’s cost. Once generics do arrive, the price should drop substantially, as it does for most branded heart failure medications.
How It Differs From Cheaper Alternatives
A common question is why doctors don’t simply prescribe a beta-blocker instead. The answer is that Corlanor isn’t a substitute for beta-blockers. It’s an add-on for patients already taking them at the highest dose they can handle, or a workaround for patients who genuinely can’t take them.
Beta-blockers work broadly. They block adrenaline’s effects across the heart, lungs, and blood vessels, which is why they can cause side effects like fatigue, dizziness from low blood pressure, and breathing difficulties. Ivabradine’s mechanism is far more targeted. It only reduces the rate at which the heart’s pacemaker cells fire, leaving blood pressure, cardiac output, and lung function untouched. That selectivity makes it uniquely useful for a specific clinical scenario, but it also means it was developed and tested for a condition where no cheap generic already existed. Drugs that fill unmet medical needs command higher prices because there is no competitive alternative forcing the price down.
The Cost of Development and Exclusivity
Bringing a new cardiac drug to market involves large-scale clinical trials in heart failure patients, a population that requires long follow-up periods to measure outcomes like hospitalization and survival. The pivotal trial that led to Corlanor’s approval enrolled thousands of patients across multiple countries and tracked them for years. Those costs, combined with the regulatory process and post-approval safety monitoring, are built into the price during the years of market exclusivity. For a drug with a relatively small target population, each prescription carries a larger share of that investment compared to a blockbuster drug prescribed to millions.
What You Can Do About the Cost
If you’re prescribed Corlanor and the price is a barrier, there are a few practical options worth exploring.
The Amgen Safety Net Foundation provides Corlanor at no cost to eligible patients. To qualify, you need to have lived in the U.S. for at least six months and have no insurance coverage (or, for certain products, be a Medicare patient with an affordability gap and no access to other financial assistance). Income limits for 2026 are generous: up to $79,800 for a single-person household, $108,200 for two people, $136,600 for three, and $165,000 for four, with $28,400 added per additional household member. Limits run about 25% higher in Alaska and 15% higher in Hawaii.
Beyond manufacturer programs, many patients find savings through insurance formulary exceptions, copay cards (for commercially insured patients), or state pharmaceutical assistance programs. If you have insurance but face a high copay, asking your cardiologist’s office to submit a prior authorization or appeal can sometimes move the drug to a lower cost tier. Specialty pharmacies occasionally offer better pricing than retail chains as well.
The arrival of generic ivabradine, expected in the coming years based on current patent timelines, should be the most significant price relief. When that happens, the cost of this medication will likely fall in line with other generic heart failure drugs.